Chronic spontaneous urticaria activity, impact and control as well as their changes are strongly linked, and these links are not affected by angioedema or comorbid inducible urticaria - Results from the validation of the Polish Urticaria Control Test.
Angioedema
Control
UCT
Urticaria
Validation
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
05
10
2021
revised:
31
12
2021
accepted:
07
02
2022
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
12
4
2022
Statut:
epublish
Résumé
Monitoring the effects of treatment on disease activity, impact, and control in patients with chronic spontaneous urticaria (CSU) is essential. We do not have enough information on how these features of CSU and its response to treatment are linked. Also, there is no information on how recurrent angioedema or coexisting chronic inducible urticaria (CIndU) affect their relation. The aim of this study was to analyse the link between disease activity, impact, and control in CSU patients and possible effects of recurrent angioedema and comorbid CIndU. To perform these analyses, we validated the Polish version of the Urticaria Control Test (UCT) in 106 chronic urticaria patients. The relationship between CSU activity, impact, and control was assessed in regard to recurrent angioedema and coexisting CIndU. The Polish UCT showed high levels of validity, reliability, and sensitivity to change. Disease activity, impact, and control as well as their changes, assessed by the UAS, the CU-Q In CSU, there is a strong, albeit not perfect correlation of disease activity, impact, and control, which underlines the need to assess all 3 features of the disease in routine clinical practice. Recurrent angioedema and comorbid CIndU, which are both common and relevant in CSU, do not affect how disease activity, impact and control in patients with CSU are related to each other.
Sections du résumé
Background
UNASSIGNED
Monitoring the effects of treatment on disease activity, impact, and control in patients with chronic spontaneous urticaria (CSU) is essential. We do not have enough information on how these features of CSU and its response to treatment are linked. Also, there is no information on how recurrent angioedema or coexisting chronic inducible urticaria (CIndU) affect their relation. The aim of this study was to analyse the link between disease activity, impact, and control in CSU patients and possible effects of recurrent angioedema and comorbid CIndU.
Methods
UNASSIGNED
To perform these analyses, we validated the Polish version of the Urticaria Control Test (UCT) in 106 chronic urticaria patients. The relationship between CSU activity, impact, and control was assessed in regard to recurrent angioedema and coexisting CIndU.
Results
UNASSIGNED
The Polish UCT showed high levels of validity, reliability, and sensitivity to change. Disease activity, impact, and control as well as their changes, assessed by the UAS, the CU-Q
Conclusions
UNASSIGNED
In CSU, there is a strong, albeit not perfect correlation of disease activity, impact, and control, which underlines the need to assess all 3 features of the disease in routine clinical practice. Recurrent angioedema and comorbid CIndU, which are both common and relevant in CSU, do not affect how disease activity, impact and control in patients with CSU are related to each other.
Identifiants
pubmed: 35399816
doi: 10.1016/j.waojou.2022.100635
pii: S1939-4551(22)00011-4
pmc: PMC8938623
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100635Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
Authors declare no conflict of interest.
Références
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):2055-2056.e4
pubmed: 30731179
J Allergy Clin Immunol. 2014 May;133(5):1365-72, 1372.e1-6
pubmed: 24522090
Actas Dermosifiliogr. 2015 Nov;106(9):746-52
pubmed: 26164835
Allergy. 2017 Dec;72(12):2005-2016
pubmed: 28543019
J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1185-1190.e1
pubmed: 29128337
J Dermatol Sci. 2011 Apr;62(1):36-41
pubmed: 21333502
Value Health. 2005 Mar-Apr;8(2):94-104
pubmed: 15804318
Allergy. 2009 Jun;64(6):927-36
pubmed: 19453340
Allergy. 2018 Jul;73(7):1393-1414
pubmed: 29336054
Allergy. 2018 Jan;73(1):251-255
pubmed: 28815631
Health Qual Life Outcomes. 2016 Apr 14;14:61
pubmed: 27075142
World Allergy Organ J. 2019 Jan 26;12(1):100009
pubmed: 30937134
J Allergy Clin Immunol Pract. 2017 Mar - Apr;5(2):464-470
pubmed: 27838325
Allergy. 2019 Dec;74(12):2542-2544
pubmed: 31169906
Allergol Int. 2019 Apr;68(2):279-281
pubmed: 30527936
Ann Allergy Asthma Immunol. 2019 May;122(5):539-541
pubmed: 30769182
Int J Dermatol. 2020 Aug;59(8):893-901
pubmed: 32638368
Clin Exp Dermatol. 2010 Dec;35(8):869-73
pubmed: 20456386
Saudi Med J. 2017 Dec;38(12):1230-1236
pubmed: 29209673
Allergy. 2005 Aug;60(8):1073-8
pubmed: 15969690
Allergy Asthma Proc. 2020 May 1;41(3):e61-e66
pubmed: 32375971
Allergy Asthma Immunol Res. 2019 Jan;11(1):55-67
pubmed: 30479077
Am J Clin Dermatol. 2018 Apr;19(2):267-274
pubmed: 29368043
J Allergy Clin Immunol. 2017 Dec;140(6):1710-1713.e11
pubmed: 28625805